Cancer Research
Newswire |
SEATTLE, February 18 /PRNewswire/ --
- Seattle Children's receives US$1 million Gates Foundation grant for research and international summit
Seattle Children's Hospital Research Institute announced today that it has received a US$1 million grant from the Bill & Melinda Gates Foundation to study ways to prevent global prematurity and stillbirth. Prematurity claims the lives of over 1 million newborn babies worldwide each year. It is the leading cause of infant mortality in the United States with over 10,000 babies dying each year. Over 3 million babies are stillborn each year…
Researchers have provided the first global analysis of human proteins interacting with proteins of viruses and other pathogens. The network of interactions, described in an article published February 15 in the open-access journal PLoS Pathogens, reveals possible key intervention points for the future development of therapeutics against infectious diseases.
“Infectious diseases result in millions of deaths each year,” said co-author Matt Dyer. “Although much effort has been directed towards the study of how infection by a pathogen causes disease in humans, only recently have large data sets…
Newswire |
LUGANO, Switzerland, February 13 /PRNewswire/ -- Helsinn Healthcare SA, a Swiss pharmaceutical group, today announced that it has signed a Distribution and License Agreement for Aloxi(R) (Palonosetron hydrochloride) and Gelclair(R) in Germany with Riemser Arzneimittel AG, a medium-sized pharmaceutical group engaging in research, headquartered in the West Pomeranian town of Greifswald - Island of Riems, Germany.
Aloxi(R) is a patented second generation 5-HT3 antagonist, which is differentiated by its strength on initiation and the duration of its activity. Aloxi(R) obtained a centralized…
Newswire |
CAMBRIDGE, Massachusetts, February 12 /PRNewswire/ --
Mersana, a cancer therapeutics company, announced today that Timothy B. Lowinger, Ph.D., has joined the company as Chief Scientific Officer.
"We are thrilled that Tim is now a part of the Mersana team," said Julie A. Olson, President and CEO at Mersana. "His extensive leadership in oncology research and his experience with polymer-based drug systems are an ideal match for Mersana. In addition to the important impact he will have on our newest programs, his contributions toward advancing our lead product, XMT-1001, and our second product,…
Newswire |
FREDERICK, Maryland, February 11 /PRNewswire/ --
Cancer research pioneer Michael G. Hanna Jr. Ph.D., also Vaccinogen, Inc.'s Founder, Chairman and CEO has acquired the rights to OncoVAX(R), a vaccine with the potential to prevent colon cancer from recurring in many patients.
"This agreement represents a major step forward in defeating cancer by increasing the body's immunity to it," said Dr. Hanna, who has been working on cancer vaccines for more than 30 years.
In the agreement, Vaccinogen obtained exclusive license to OncoVAX(R) Active Specific Immunotherapy as well as an important…
Newswire |
LUGANO, Switzerland, February 11 /PRNewswire/ -- Helsinn Healthcare SA, a Swiss pharmaceutical group, is pleased to announce, ahead of schedule, today's launch in the UK of Aloxi(R) (Palonosetron hydrochloride), a new generation treatment for chemotherapy, induced nausea and vomiting, by its local partner Maelor plc, the specialist hospital medicines group.
Aloxi(R) is a patented second generation 5-HT3 antagonist, which is differentiated by its strength on initiation and the duration of its activity. Aloxi(R) obtained a centralized registration in Europe in 2005, with an indication for…
Mount Sinai researchers have discovered that the release of blood stem cells from bone marrow is regulated by the brain through the cyclical human biological clock, via adrenergic signals transmitted by the sympathetic nervous system. These new findings, published online today on the website of the journal Nature, point out that the harvest of stem cells for transplantation may be improved by timing it at the peak of their release.
The study describes the mechanisms at the molecular levels in which signals from the biological clock in the brain are sent via the sympathetic—or "fight or flight…
Continued from Part 6:
I interviewed Gary Taubes by phone a few weeks ago, shortly after he gave a talk about the main ideas of his new book — Good Calories, Bad Calories — at UC Berkeley. The interview lasted about 2 hours. This is part 7.
SETH ROBERTS: I was a member of the Center for Weight and Health. But the other members didn’t know what I was up to, and had no idea it could have anything to do with actual weight loss.
GARY TAUBES: That’s one of the things I’ve found most amusing about obesity research, that you have this disconnect from pre-World War Two, when the people doing it were…
Newswire |
MONTREAL, Canada, February 6 /PRNewswire/ --
- Shipment of Prion Capture Resin to MacoPharma in Q1 2008;
- MacoPharma Increased its Forecast for P-Capt(R) Filters Sale in 2008;
- Use of Affinity Prion Adsorbent for Plasma-Derived Products to Generate in Excess of CAD$25 M Over the Next 5 Years - CAD$4 M in 2008;
- 10th Product Approved by the FDA and or the EMEA, Contributing to Revenue Growth.
ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") today provided an update on its business activities.
"Key milestones were achieved in January, a prelude to the announced growth for 2008 and…
Antioxidants are believed to help ward off illness and boost the body’s immune system by acting as free radical scavengers, helping to mop up cell damage caused by free radicals. But you don't have to pay a lot; the humble white button mushroom (Agaricus bisporus) has as much, and in some cases, more antioxidant properties than more expensive varieties.
Although the button mushroom is the foremost cultivated edible mushroom in the world with thousands of tons being eaten every year, it is often thought of as a poor relation to its more exotic and expensive cousins and to have lesser value…